Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center

Leukemia Research

Volumn 38, Issue 12, 2014, Pages 1435-1440

  Qin, Ya Zhen ^a   Zhu, Hong Hu ^a   Jiang, Qian ^a   Jiang, Hao ^a   Zhang, Le Ping ^a   Xu, Lan Ping ^a   Wang, Yu ^a   Liu, Yan Rong ^a   Lai, Yue Yun ^a   Shi, Hong Xia ^a   Jiang, Bin ^a   Huang, Xiao Jun ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Tsinghua University   (China)

Author keywords

C KIT mutations; Core binding factor acute myeloid leukemia; Inv(16); Prognosis; T(8 ; 21)

Indexed keywords

AML1 ETO PROTEIN; ANTHRACYCLINE DERIVATIVE; CORE BINDING FACTOR; CORE BINDING FACTOR BETA MYH11 PROTEIN; CYTARABINE; ETOPOSIDE; HYBRID PROTEIN; IDARUBICIN; UNCLASSIFIED DRUG; AML1-ETO FUSION PROTEIN, HUMAN; ONCOPROTEIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CHILD; CHROMOSOME 16; CHROMOSOME INVERSION; CHROMOSOME INVERSION 16; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; EXON; GENE MUTATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; ONCOGENE C KIT; OVERALL SURVIVAL; AGE; CHINA; CHROMOSOME 21; CHROMOSOME 8; CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; FOLLOW UP; GENETICS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; PREVALENCE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CHINA; CHROMOSOME INVERSION; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; ONCOGENE PROTEINS, FUSION; PREVALENCE; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL RATE;

EID: 84916201282     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.09.017     Document Type: Article

References (39)

1. Lenny N., Meyers S., Hiebert S.W. Functional domains of the t(8;21) fusion protein AML-1/ETO. Oncogene 1995, 11:1761-1769.
2. Liu P., Tarlé S.A., Hajra A., Claxton D.F., Marlton P., Freedman M., et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993, 261:1041-1044.
3. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood 1998, 96:4075-4083.
4. Bloomfield C.D., Lawrence D., Byrd J.C., Carroll A., Pettenati M.J., Tantravahi R., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998, 58:4173-4179.
5. Byrd J.C., Mrózek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Cancer and Leukemia Group B (CALGB 8461), pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
6. Marcucci G., Mrózek K., Ruppert A.S., Maharry K., Kolitz J.E., Moore J.O., et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005, 23:5705-5717.
7. Besmer P., Murphy J.E., George P.C., Qui F., Bergold P.J., Ledermann L., et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986, 320:415-421.
8. Qui F., Ray P., Brown K., Barker P.E., Jhanwar S., Ruddle F.H., et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988, 7:1003-1011.
9. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993, 92:1736-1744.
10. Beghini A., Cairoli R., Morra E., Larizza L. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol Dis 1998, 24:262-270.
11. Gari M., Goodeve A., Wilson G., Winship P., Langabeer S., Linch D., et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999, 105:894-900.
12. Goemans B.F., Zwaan C.M., Miller M., Zimmermann M., Harlow A., Meshinchi S., et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19:1536-1542.
13. Beghini A., Ripamonti C.B., Cairoli R., Cazzaniga G., Colapietro P., Elice F., et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004, 89:920-925.
14. Wang Y.Y., Zhou G.B., Yin T., Chen B., Shi J.Y., Liang W.X., et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A 2005, 102:1104-1109.
15. Care R.S., Valk P.J., Goodeve A.C., Abu-Duhier F.M., Geertsma-Kleinekoort W.M., Wilson G.A., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003, 121:775-777.
16. Paschka P., Marcucci G., Ruppert A.S., Mrózek K., Chen H., Kittles R.A., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006, 24:3904-3911.
17. Hoyos M., Nomdedeu J.F., Esteve J., Duarte R., Ribera J.M., Llorente A., et al. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. Eur J Haematol 2013, 91:209-218.
18. Cairoli R., Beghini A., Grillo G., Nadali G., Elice F., Ripamonti C.B., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006, 107:3463-3468.
19. Boissel N., Leroy H., Brethon B., Philippe N., de Botton S., Auvrignon A., et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006, 20:965-970.
20. Pollard J.A., Alonzo T.A., Gerbing R.B., Ho P.A., Zeng R., Ravindranath Y., et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010, 115:2372-2379.
21. Park S.H., Chi H.S., Min S.K., Park B.G., Jang S., Park C.J. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011, 35:1376-1383.
22. Shimada A., Taki T., Tabuchi K., Tawa A., Horibe K., Tsuchida M., et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006, 107:1806-1809.
23. Jourdan E., Boissel N., Chevret S., Delabesse E., Renneville A., Cornillet P., et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013, 121:2213-2223.
24. Manara E., Bisio V., Masetti R., Beqiri V., Rondelli R., Menna G., et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia 2014, 28:1132-1134.
25. Paschka P., Du J., Schlenk R.F., Gaidzik V.I., Bullinger L., Corbacioglu A., et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood 2013, 121:170-177.
26. Patel J.P., Gönen M., Figueroa M.E., Fernandez H., Sun Z., Racevskis J., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
27. National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN Guidelines): acute myeloid leukemia. Version 2 2014.
28. Döhner H., Estey E.H., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
29. Zhu H.H., Zhang X.H., Qin Y.Z., Liu D.H., Jiang H., Chen H., et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 2013, 121:4056-4062.
30. Qin Y., Zhu H., Jiang B., Li J., Lu X., Li L., et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res 2009, 33:384-390.
31. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003, 17:2318-2357.
32. Beillard E., Pallisgaard N., van der Velden V.H., Bi W., Dee R., van der Schoot E., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQPCR)-a Europe against cancer program. Leukemia 2003, 17:2474-2486.
33. Shimada A., Taki T., Kubota C., Itou T., Tawa A., Horibe K., et al. N822 mutation of KIT gene was frequent in pediatric acute myeloid leukemia patients with t(8;21) in Japan: a study of the Japanese childhood AML cooperative Study Group. Leukemia 2007, 21:2218-2219.
34. Nick H.J., Kim H.G., Chang C.W., Harris K.W., Reddy V., Klug C.A. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia. Blood 2012, 119:1522-1531.
35. Billström R., Johansson B., Fioretos T., Garwicz S., Malm C., Zettervall O., et al. Poor survival in t(8;21) (q22;q22)-associated acute myeloid leukaemia with leukocytosis. Eur J Haematol 1997, 59:47-52.
36. Nguyen S., Leblanc T., Fenaux P., Witz F., Blaise D., Pigneux A., et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML intergroup. Blood 2002, 99:3517-3523.
37. Leroy H., de Botton S., Grardel-Duflos N., Darre S., Leleu X., Roumier C., et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 2005, 19:367-372.
38. Cairoli R., Grillo G., Beghini A., Tedeschi A., Ripamonti C.B., Larizza L., et al. C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index. Leukemia 2003, 17:471-472.
39. Schlenk R.F., Benner A., Krauter J., Büchner T., Sauerland C., Ehninger G., et al. Individual patient data-based meta-analysis of patients aged 16-60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004, 22:3741-3750.